UK markets closed
NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.18 -0.62 (-0.78%) GOLD FUTURES
2,423.60 -14.90 (-0.61%) DOW
39,839.37 +32.60 (+0.08%) Bitcoin GBP
54,763.57 +977.73 (+1.82%)
BridgeBio Pharma, Inc. (BBIO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:25PM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 5.52B |
| Enterprise value | 6.73B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 22.86 |
| Price/book (mrq) | N/A |
| Enterprise value/revenue | 30.80 |
| Enterprise value/EBITDA | -9.15 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.08 |
| 52-week change 3 | 116.11% |
| S&P500 52-week change 3 | 28.04% |
| 52-week high 3 | 44.32 |
| 52-week low 3 | 12.75 |
| 50-day moving average 3 | 27.84 |
| 200-day moving average 3 | 30.59 |
Share statistics
| Avg vol (3-month) 3 | 1.64M |
| Avg vol (10-day) 3 | 1.46M |
| Shares outstanding 5 | 187.13M |
| Implied shares outstanding 6 | 187.13M |
| Float 8 | 121.21M |
| % held by insiders 1 | 5.24% |
| % held by institutions 1 | 94.94% |
| Shares short (30 Apr 2024) 4 | 16.23M |
| Short ratio (30 Apr 2024) 4 | 10.52 |
| Short % of float (30 Apr 2024) 4 | 13.38% |
| Short % of shares outstanding (30 Apr 2024) 4 | 8.67% |
| Shares short (prior month 28 Mar 2024) 4 | 14.28M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | -246.23% |
| Operating margin (ttm) | 1.77% |
Management effectiveness
| Return on assets (ttm) | -40.08% |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | 218.6M |
| Revenue per share (ttm) | 1.29 |
| Quarterly revenue growth (yoy) | 11,461.90% |
| Gross profit (ttm) | N/A |
| EBITDA | -466.45M |
| Net income avi to common (ttm) | -538.26M |
| Diluted EPS (ttm) | -3.23 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 519.69M |
| Total cash per share (mrq) | 2.78 |
| Total debt (mrq) | 1.73B |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 5.54 |
| Book value per share (mrq) | -5.61 |
Cash flow statement
| Operating cash flow (ttm) | -602.93M |
| Levered free cash flow (ttm) | -382.72M |
© 2024 Yahoo. All rights reserved.